A Population-based Study Of Progression And Risk Factors For Age-related Maculopathy
Funder
National Health and Medical Research Council
Funding Amount
$776,022.00
Summary
Age-related macular degeneration (AMD) is a progressive disease, commencing with the less severe age-related maculopathy (ARM), that ultimately can lead to the loss of fine central vision and personal independence. People with advanced AMD generally retain some mobility if their peripheral vision is maintained, but they are unable to perform tasks such as reading, hobbies or recognising people's faces. Unfortunately, the available treatment for AMD, macular laser photocoagulation, benefits only ....Age-related macular degeneration (AMD) is a progressive disease, commencing with the less severe age-related maculopathy (ARM), that ultimately can lead to the loss of fine central vision and personal independence. People with advanced AMD generally retain some mobility if their peripheral vision is maintained, but they are unable to perform tasks such as reading, hobbies or recognising people's faces. Unfortunately, the available treatment for AMD, macular laser photocoagulation, benefits only a minority of people with this disease. Until safe and effective treatments for AMD can be developed, identification of major risk factors for the development and progression of AMD is essential to determine if interventions aimed at primary prevention can be initiated. This project will expand on the initial findings of the Visual Impairment Project (VIP), a population-based study of age-related eye disease in a cohort of more than 5000 Victorians aged 40 years and older. Data from the VIP have shown that AMD is the most important ophthalmologic public health problem, particularly since AMD is the major cause of vision impairment in Australia and has the least available treatment options. This study will follow individuals who were identified in the VIP with ARM-AMD to determine the natural history and risk factors associated with the longer term progression of AMD. Particular emphasis will be on determining the role of cardiovascular disease risk factors in AMD progression.Read moreRead less
Metabolic Syndrome, Inflammation And Non-alcoholic Fatty Liver Disease In Busselton
Funder
National Health and Medical Research Council
Funding Amount
$351,300.00
Summary
The metabolic syndrome is a clustering of obesity, insulin resistance, high cholesterol and high blood pressure. It could affect up to 30% of the population and often leads to diabetes and heart disease. Fatty liver disease is a chronic liver condition that often has no symptoms but can lead to serious liver damage. It could affect up to 25% of the population and is common even in people who drink very little alcohol. The rising prevalence of obesity in Australia suggests that the metabolic synd ....The metabolic syndrome is a clustering of obesity, insulin resistance, high cholesterol and high blood pressure. It could affect up to 30% of the population and often leads to diabetes and heart disease. Fatty liver disease is a chronic liver condition that often has no symptoms but can lead to serious liver damage. It could affect up to 25% of the population and is common even in people who drink very little alcohol. The rising prevalence of obesity in Australia suggests that the metabolic syndrome and fatty liver disease may be on the increase and therefore so too could diabetes and heart disease which already consume significant health resources. Using the unique health data collection of the Busselton Health Study in Western Australia, this project will help to determine how common these conditions are in Australia and lead to a better understanding of the nature and causes of these conditions including the possible role of chronic inflammation. This important information will be used to provide opportunities for better risk assessment, disease prevention, and earlier intervention.Read moreRead less
Tracking The Impact Of Drug Regulatory Actions: Consumer Health Outcomes, Risk-benefit Issues And Policy Framework.
Funder
National Health and Medical Research Council
Funding Amount
$439,324.00
Summary
This study will explore what happens in the community when a medicine is withdrawn from the market or discredited due to safety concerns. It will examine the impacts of two recent cases of medicine withdrawal or serious long-term safety concern, on a large cohort of women with high utilisation rates who were monitored during the time the medicines were discredited. The study will be an important guide to future regulatory, media and provider responses when medicines are discredited.
The Predictors Of Prostate Cancer In The Melbourne Collaborative Cohort Study
Funder
National Health and Medical Research Council
Funding Amount
$358,457.00
Summary
In 1990 we set up a long-term study of diet and health. The aim was to measure diet and other risk factors in healthy people in order to see how they might affect future development of cancer. To do this we recruited 41,500 people aged 40 to 69, measured what they ate and drank, and collected information on other aspects of lifestyle, medical history, and family history of common diseases. All had height and weight and blood pressure measured and gave a blood sample. People were selected so that ....In 1990 we set up a long-term study of diet and health. The aim was to measure diet and other risk factors in healthy people in order to see how they might affect future development of cancer. To do this we recruited 41,500 people aged 40 to 69, measured what they ate and drank, and collected information on other aspects of lifestyle, medical history, and family history of common diseases. All had height and weight and blood pressure measured and gave a blood sample. People were selected so that men and women and migrants from Italy and Greece would be included. In this way we could widen the range of dietary habits, other lifestyle factors and genetic variation (measured in DNA from blood). Since then participants have completed another questionnaire and instances of disease have been noted from self reports and from examining medical records. We want to analyse data from 700 men in the study who have developed prostate cancer (PC). First we will analyse data collected on all 17,000 men (collected when joining the study, and at follow up). Next we will use data from only the 700 men with PC and 1400 men who have not developed PC. This study will focus on measuring substances in the blood. We want to measure a range of fats, vitamins, antioxidants and phytoestrogens, as well as male sex hormones and related substances. In the DNA from the blood we plan to measure variations in genes that influence how male sex hormones and other growth factors important in the prostate are produced and used. We will then be able to estimate what affect these factors have on the risk of getting PC. We will also be able to see if any of them act together to make the risk of PC much higher in certain men. This work should identify what lifestyle factors could reduce the risk of PC. It should also identify what genetic variations are associated with increased risk of PC and thus identify a sub group of men who might benefit from early medical attention or from changes in lifestyle.Read moreRead less